Open access
Open access
Powered by Google Translator Translator

#ESCCongress – RCT: Finerenone reduced CV events in patients with kidney disease and type 2 diabetes (12.4% vs. 14.2% during a median follow-up of 3.4 years), but the risk of hyperkalemia was increased (10.8% vs. 5.3%).

29 Aug, 2021 | 18:14h | UTC

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes – New England Journal of Medicine

News release: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology


Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease – FIGARO-DKD – American College of Cardiology

FIGARO-DKD and FIDELITY Findings Show Benefits of Finerenone to Improve Outcomes in Patients With Kidney Disease, Diabetes – American College of Cardiology


[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.